{"id":"W2012098025","doi":"10.3109/10428194.2010.546015","title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Alberta Cancer Foundation; University Health Network; Queen Elizabeth II Health Sciences Centre; Juravinski Hospital","funders":"National Cancer Institute","keywords":"Gemcitabine; Bortezomib; Mantle cell lymphoma; Medicine; Internal medicine; Oncology; Adverse effect; Chemotherapy; Refractory (planetary science); Phases of clinical research; Lymphoma; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002121599,0.0007134531,0.002289033,0.0002508924,0.0003124361,0.00003345714,0.0003958075,0.0004193626,0.0001280613],"category_scores_gemma":[0.0005944296,0.0005089969,0.0003113152,0.0005834536,0.0005210735,0.0002205011,0.0003298056,0.0001319538,0.000002585022],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.00440947,"about_ca_system_score_gemma":0.01082624,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.6153727,"about_ca_topic_score_gemma":0.225327,"domain_scores_codex":[0.9936731,0.000615981,0.002806491,0.001113561,0.001115541,0.000675291],"domain_scores_gemma":[0.9959168,0.00134483,0.001211361,0.0007303939,0.0003007128,0.0004958372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01523111,0.02828552,0.581189,0.0003919972,0.003032921,0.001371409,0.01119536,0.00002510259,0.002135988,0.001090198,0.01205855,0.3439929],"study_design_scores_gemma":[0.1792274,0.003949317,0.8017941,0.0004395838,0.001140491,0.0001113319,0.001976966,0.0008691282,0.004189355,0.0002731788,0.005492006,0.000537226],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990741,0.003886436,0.000004261097,0.0001619831,0.0007055979,0.001830637,0.0004753099,0.00003614631,0.0021587],"genre_scores_gemma":[0.9963504,0.00136068,0.0002957817,0.0008445946,0.0003404025,0.0003497604,0.0001133221,0.00006645341,0.0002785814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3900457,"threshold_uncertainty_score":0.9997362,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07482145748558373,"score_gpt":0.3398540940634834,"score_spread":0.2650326365778997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}